Information on the impact of bone metastasis and skeletal-related events (SREs) on mortality among prostate cancer patients is limited. Using the linked Surveillance, Epidemiology and End Results (SEER)-Medicare database, we identified men aged 65 years or older diagnosed with prostate cancer between July 1 1999 and December 31 2005 and followed to determine deaths through December 31 2006. We classified subjects as having bone metastasis and SREs as indicated by Medicare claims. Using Cox regression, we estimated mortality hazards ratios (HR) among men with bone metastasis with or without SRE, compared with men without bone metastasis. Among 126 978 men with prostate cancer (median follow-up, 3.3 years), 9746 (7.7%) had bone metastasis at prostate cancer diagnosis (1.7%) or during follow-up (5.9%). SREs occurred in 4296 (44%) men with bone metastasis. HRs for risk of death were 6.6 (95% CI ¼ 6.4-6.9) and 10.2 (95% CI ¼ 9.8-10.7), respectively, for men with bone metastasis but no SRE and for men with bone metastasis plus SRE, compared with men without bone metastasis. Bone metastasis was associated with mortality among prostate cancer patients. This association appeared to be stronger for bone metastasis plus SRE than for bone metastasis without SRE.
Introduction
Prostate cancer is the most frequently diagnosed noncutaneous cancer and the second leading cause of cancer deaths among men in the United States. 1 The 5-year relative survival among men aged 65 years or older is 99.8% for all tumor stage groups combined but is considerably lower (5%) among men with distant metastatic disease at diagnosis.
About 70-80% of patients with metastatic prostate cancer present with or develop bone metastasis [2] [3] [4] and are at increased risk for skeletal-related events (SREs), which include pathological fractures, spinal cord compression and severe pain requiring radiotherapy or surgery for bone lesions. These SREs result in significant complications that reduce quality of life. 5 Data are limited on the occurrence and outcomes of bone metastasis among elderly men who develop prostate cancer. A few population-based observational studies have reported results pertaining to the occurrence bone metastases and SREs among prostate cancer patients, [6] [7] [8] [9] but none has focused on older men. We therefore quantified the impact of bone metastasis and SREs on mortality among older prostate cancer patients in the US by analyzing a combined population-based cancer registry and Medicare claims database.
Materials and methods

Data source
We analyzed linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data for the time period 1999-2006. 10, 11 The SEER program collects cancer incidence and survival data from population-based cancer registries, covering 14-26% of the US population. SEER data included information on patient demographics, date of cancer diagnosis and tumor stage. The Medicare program covers 97% of US population aged X65 years. 12 Medicare data included demographic information and claims data (dates of service, diagnosis codes (ICD-9) and procedure (current procedural terminology codes)) from hospitals and other institutional and non-institutional providers.
Study population
We identified a cohort of men aged 65 years or older and having a SEER record of a new diagnosis of prostate cancer between July 1 1999 and December 31 2005 and used SEER and Medicare data to determine the occurrence of bone metastasis, SREs and deaths occurring through December 31 2006. We required each subject to have a baseline period of at least 6 months of full fee-forservice Medicare coverage before his prostate cancer diagnosis date. The claims data from this baseline period provided information on comorbidities and on the presence of possible bone metastasis and SREs at cancer diagnosis. We excluded men who did not have both Medicare part A and part B coverage and those who were enrolled in a Medicare Advantage plan during the baseline period because we did not have complete Medicare claims data on the services they received. In all analyses, we censored subjects if they died or lost full fee-for-service coverage before the end of 2006.
Bone metastasis and SREs
We apply the term 'bone metastasis' and 'SREs' to men who have claims-based evidence of these conditions. We used the following Medicare claims data as evidence of bone metastasis: (a) at least one inpatient claim with an ICD-9 diagnosis code of 198.5 ('secondary malignant neoplasm of bone and bone marrow') as the primary or secondary discharge diagnosis; (b) at least one outpatient claim with a diagnosis code of 198.5, paired with a code for procedures used to diagnose or treat bone metastasis; or (c) at least one outpatient physician claim with a diagnosis code of 198.5 (algorithm available on request). We classified subjects as having concurrent bone metastasis at the time of diagnosis if they had a claim in the month of the prostate cancer diagnosis or in the preceding month. Among subjects without concurrent bone metastasis at diagnosis, we identified new bone metastasis as the earliest occurrence of one of the above claims patterns at any time during follow-up.
We defined SREs as one or more of the following conditions, occurring concurrently with or after the first bone metastasis: fractures, radiotherapy to bone, surgery to bone and spinal cord compression. We identified SREs using combinations of diagnosis and procedure codes from inpatient and/or outpatient claims (codes available on request). We classified an SRE as concurrent with bone metastasis if it occurred within 30 days before or after the earliest bone metastasis date and as subsequent to bone metastasis if it occurred at any time more than 30 days after the bone metastasis date. We chose a 30-day window before and after diagnosis of bone metastasis for classification as a concurrent SRE because the claims data may not provide exact dates of diagnosis. We excluded from the analysis patients with claims suggesting bone metastases occurring more than 30 days before the prostate cancer diagnosis (n ¼ 391).
Mortality
We obtained information on date of death using the combined SEER registry and Medicare claims data. We used the concordant date of death in these two sources, if there was agreement between them. If they were discrepant, we used the SEER death date. If the SEER date of death was missing, we used the Medicare date of death.
Covariates
From the SEER data, we obtained information on age, race/ethnicity and stage at cancer diagnosis. The SEER classifies stage based on the extent of cancer spread from the site of origin documented in medical records within 2 months of diagnosis. The staging scheme includes four stages: localized-tumor confined to the prostate; regional-tumor that has extended beyond the prostate capsule into surrounding organs/tissue and/or lymph nodes; distant-tumor has extended to parts of the body remote from the prostate; and unstaged-information not sufficient to assign a stage. Prostate cancer cases undergoing radical prostatectomy may be reclassified from clinically localized to regional stage disease based on the operative or pathology reports. Therefore, SEER combines local and regional stages because of the large proportion of cases that are upstaged because of surgery. 13 From the Medicare claims data, we obtained information on comorbidities. We computed each person's Charlson comorbidity score on the basis of ICD-9 diagnosis codes in his inpatient records for the 17 medical conditions (Table 1 ) comprising the Charlson index in the 12-month period before the month of cancer diagnosis.
14,15
Statistical analysis
Descriptive analyses of the cohort included frequency distributions and median values, where applicable. We computed the proportion of men with prostate cancer having claims-based evidence of bone metastasis at 3 years from diagnosis overall and for subgroups specified by tumor stage at diagnosis. 16, 17 For these computations, we selected men diagnosed with prostate cancer from July 1 1999 to December 31 2002, so that these men would have a potential observation period of up to 3 years post prostate cancer diagnosis. Other analyses were unrestricted with regard to length of observation.
We used Cox regression analyses to estimate mortality hazards ratios (HRs) and 95% CIs among men with bone metastasis with or without SREs, compared with men without bone metastasis, adjusting for covariates. 18 In one set of analyses restricted to subjects with bone metastasis, we estimated the mortality HR among men with bone metastasis and SREs, compared with men with bone metastasis but without SRE, adjusting for covariates. Confounders were categorical forms of age at cancer diagnosis (65-69, 70-74, 75-79, 80-84, 85 þ ), race (white, African American, Hispanic American, other), stage at diagnosis (distant, localized/regional, unstaged) and Charlson comorbidity score (0, 1, 2, 3 þ ). Analyses were performed using SAS (Cary, NC).
This study was approved by the University of Alabama at Birmingham (UAB) Institutional Review Board and by the NCI SEER-Medicare Program.
Results
The overall cohort of 126 978 men was predominantly white (79%) with a median age at diagnosis of 74 years Death from bone involvement in prostate cancer N Sathiakumar et al and a median follow-up of 3.3 years (Table 1) . During the study period, 9746 (7.7%) men had claims-based evidence of bone metastasis either concurrently with the diagnosis of prostate cancer diagnosis (n ¼ 2208) or during follow-up (n ¼ 7538). The median time for all stages combined from cancer diagnosis bone metastasis was 17.1 months among men without a bone metastasis at diagnosis.
Bone metastasis at prostate cancer diagnosis or during follow-up
Men with a bone metastasis were more likely to be diagnosed with cancer relatively early during the study period, to be 80 þ years of age, to have a shorter median follow-up period (2.2 years vs 3.5 years) and to have a higher proportion of deaths (73 vs 19%) than men without bone metastasis. Men with bone metastasis were similar to men without bone metastasis with regard to race and comorbidity (Table 1 ). Figure 1 displays the proportion of men with evidence of bone metastasis at 3 years post prostate cancer diagnosis, according to stage at diagnosis, among the Death Among 1079 men with fracture as the first SRE, either as the only skeletal complication or in association with other skeletal complications, 522 (48%) had a fracture coded as pathological. The most common site of pathological fracture was the spine (n ¼ 340), followed by hip (n ¼ 98), femur (n ¼ 40), humerus (n ¼ 37) and other sites (n ¼ 7).
Age-, race-and stage-adjusted HRs for death were 6.6 (95% CI ¼ 6.4-6.9) and 10.2 (95% CI ¼ 9.8-10.7), respectively, for men with bone metastasis but no SRE and for men with bone metastasis plus SRE, compared with men without bone metastasis (Table 2) . Stage-specific analyses indicated that HRs for death associated with bone metastasis complicated with SRE was 4.8 (95% CI ¼ 4.5-5.2) for distant metastatic disease at diagnosis and 13.9 (95% CI ¼ 13.1-14.6) for localized/regional disease at diagnosis (Table 3 ). For bone metastasis without SRE, the HR for mortality was 3.0 (95% CI ¼ 2.8-3.3) for distant metastatic disease at diagnosis, and 9.2 (95% CI ¼ 8.7-9.7) for localized/regional disease at diagnosis. We found a positive association between bone metastasis and bone metastasis complicated with SRE and mortality in all categories of age groups (65-69, 70-74, 75-79, 80-84, 85 þ ). In analyses restricted to subjects with bone metastasis, the adjusted HR for death was 1.6 (95% CI ¼ 1.6-1.7) for men with bone metastasis plus SRE, compared with men with bone metastasis but without SRE.
Discussion
We found that about 7.7% of men 65 years or older with newly diagnosed prostate cancer included in the SEER program during July 1999 to December 2005 either presented with (1.7%) or subsequently developed (5.9%) a possible bone metastasis. SREs were common, occurring in 44% of these men. Having a possible bone metastasis was associated strongly with mortality among men with prostate cancer.
In our study the proportions of patients with bone metastasis at the time of prostate cancer diagnosis (1.7%) or occurring after diagnosis (5.9%) were somewhat lower than reported by others. 6, 9, 19 Of 12 005 men diagnosed between 1990-2004 in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry, 2.4% had bone metastasis at the time of diagnosis. 6 A urology unit in Italy found bone metastasis to be present in 2.5% of 1242 newly-diagnosed prostate cancer patients from November 2002 to May 2004. 19 Norgaard et al. 9 reported that 3% of 23 087 of newly diagnosed Death from bone involvement in prostate cancer N Sathiakumar et al prostate cancer patients included in the Danish National Patient Registry in 1999-2007 presented with bone metastasis at prostate cancer diagnosis, and another 11.5% developed bone metastasis during an average follow-up period of 2.2 years. The higher proportions with bone metastases reported in these three earlier studies are difficult to interpret because the investigators did not provide data on the distribution of prostate cancer patients by stage at diagnosis. Thus, differences between our results and those of the earlier studies could be due to an earlier stage distribution in our study, to differences in procedures used to detect bone metastases or both. About 50% of prostate cancer patients are expected to develop recurrent disease. 20 Despite advances in treatment, advanced prostate cancer has a propensity to metastasize to the axial skeleton resulting in considerable morbidity and mortality. 21 We observed that among men with distant-stage prostate cancer at diagnosis, 72% had evidence of bone metastasis 3 years post diagnosis. This result is consistent with findings from other studies, which reported that about 65-80% of prostate cancer patients with distant metastatic disease had a bone metastasis at diagnosis or subsequently developed a bone metastasis. 2, 3, 22, 23 In addition, autopsies of patients dying of prostate cancer indicated that up to 90% had evidence of metastatic bone disease. 24 Our results indicated that having a bone metastasis was associated with mortality among men with prostate cancer. The association appeared to be stronger for bone metastasis complicated by SRE than for bone metastasis without SRE. The Danish National Patient Registrybased study reported similar results. 9 SREs are common in metastatic prostate cancer due to frequent occurrence of bone metastasis. 25, 26, 27 SREs have a considerable impact on patients' quality of life as they affect patients' general well-being and the ability to perform basic functions of daily living. 5, 28, 29 In the present study, we found that 44% of men with possible bone metastasis had an SRE. This result agrees with findings from large-scale clinical trials of prostate cancer, reporting that SREs occurred in 50-80% of patients with bone metastasis. 3, 30, 31 The Danish National Patient Registry-based study reported that SREs occurred in 50% of 3147 prostate cancer patients with bone metastasis. 9 In our study, radiotherapy to bone was the most common SRE followed by fracture, spinal cord compression and surgery to bone. Other investigators 26, 32, 33 noted similar findings.
We observed that among patients with fractures, 48% had a pathological fracture with the spine as the most common site of occurrence. Conti et al., 8 in the observational METAURO study of prostate cancer patients enrolled at 32 urological clinics in Italy, reported that 31% of patients had pathological fractures with the spine being the most affected site. Oefelein et al. 34 suggested that skeletal fractures may be an independent and adverse risk factor for survival in prostate cancer.
Spinal metastasis can produce spinal cord compression. 35 We found that in 12% of men with SRE, spinal cord compression was the only presenting skeletal complication at the first occurrence of an SRE, and in an additional 8% of men with SRE, spinal cord compression occurred in combination with other SREs such as radiation to bone and/or fracture. Other studies also have reported that clinically evident spinal cord compression occurs in about 7-10% of patients during the course of their disease. [36] [37] [38] [39] [40] [41] Neurological impairments following spinal cord compression such as motor deficit, immobility and sphincter dysfunction may result in considerable decrement in quality and duration of life.
The strengths of the study include the use of the large population-based SEER cancer registry data and the focus on prostate cancer in the elderly. The combined cancer registry and Medicare data provide a unique opportunity to evaluate the clinical progress of prostate cancer. Other advantages of the SEER data include the continuity of data over time and the quality control measures instituted to ensure completeness of case ascertainment in the participating cancer registries.
The main limitations of our study stem from the characteristics of the SEER-Medicare data. First, our results will not be generalizable to men less than 65 years of age or men aged 65 years and above who resided in geographic areas not included in the SEER program, who only had Medicare part A coverage or, who were enrolled in Medicare Advantage plan.
Second, we have not validated the procedures used to identify bone metastasis in this study. We identified possible bone metastasis from inpatient or outpatient claims paired with selected procedure codes, an approach designed to reduce false positives. More research is needed to evaluate the use of this algorithm to identify patients with bone metastasis and to assess the addition of treatment with bisphosphonates to the algorithm. Because of potential misclassification, we may have included false positive cases or missed true cases in instances where claims were not obtained from the relevant facilities or where claims were obtained but not coded as bone metastasis. The net effect of misclassification on the observed association between bone metastasis and mortality is uncertain.
Third, potential misclassification of tumor stage exists for patients who did not have a prostatectomy. Fourth, the short time period of the study restricts follow-up and hence, limits our ability to evaluate late onset of metastatic disease. Finally, it is possible that the mortality differences we noted for men with bone metastasis or bone metastasis plus SRE compared with those without these complications may be due to uncontrolled confounding. We did not have information on treatment factors or on all comorbid conditions. However, it is not clear if these factors are likely to be confounders. In order to be a confounder, the factor must be present before the occurrence of bone metastasis (so that it is not merely an intermediate factor in the causal pathway between bone metastasis and mortality), and it must be associated both with bone metastasis and with mortality. 42 In conclusion, the present study found that having a bone metastasis as indicated by Medicare claims was associated with an increased risk of death among men with prostate cancer. This association appeared to be stronger for bone metastasis complicated by SRE than for bone metastasis without SRE. The use of bone-targeted therapies for patients who are at high risk for bone metastasis and fractures may reduce the occurrence of Death from bone involvement in prostate cancer N Sathiakumar et al SREs in this group of men and potentially reduce mortality risk in this patient population.
